Macquarie downgrades HubSpot stock rating on growth concerns By Investing.com

Macquarie downgraded HubSpot to Neutral from Outperform and cut its price target sharply to $190 from $350, citing slower net new ARR growth, longer sales cycles, and AI-related changes to the sales process. HubSpot also guided Q2 constant-currency revenue growth to 16%, below the prior quarter's 18%, while management acknowledged second-quarter booking weakness and extended AI trial periods. Analysts remain mixed, but the downgrade and reduced forward estimates point to near-term headwinds for HUBS shares.

Analysis

The market is repricing HUBS as a growth-quality name rather than a pure multiple-expansion story. The important second-order effect is that AI is not just a feature-add for HubSpot; it is changing buyer behavior, lengthening approval cycles, and creating a temporary mismatch between pipeline quality and recognized revenue. That means the stock can stay weak even if headline growth looks acceptable, because investors will wait for evidence that AI is monetizable without diluting sales productivity.

The risk is not an immediate demand collapse but a multi-quarter digestion period where bookings linearity, conversion rates, and billings visibility remain noisy. In that setup, estimate cuts tend to come in waves, and the market usually de-rates first on forward billings before it stabilizes on revenue. If management cannot show that AI-assisted selling improves close rates by mid-2026, the multiple floor is likely lower than the current debate implies.

Competitively, this opens a window for adjacent CRM / marketing automation platforms that can present a cleaner enterprise ROI narrative. Buyers evaluating AI-enabled workflows may shift budget toward vendors with clearer usage-based economics or faster implementation cycles, which pressures HUBS on both new logo acquisition and expansion. The contrarian point is that the reset may be healthier than it looks: if HubSpot is intentionally trading short-term growth smoothness for a more durable AI product cycle, the eventual rebound could be sharp once the market believes the new funnel is repeatable.

For now, the better trade is to respect the de-rating until management proves that net new ARR can re-accelerate ahead of constant-currency revenue on a sustained basis. This is a stock where the catalyst is operational proof, not valuation alone, and that usually takes at least 1-2 earnings cycles.

Key Decisions for Investors

• Stay underweight HUBS for the next 1-2 quarters; the setup favors continued estimate resets as the market waits for AI-driven sales efficiency to prove out.
• If you need exposure, prefer a put spread on HUBS 3-6 months out rather than outright short stock; downside can persist, but a sharp valuation snapback is possible if management shows improving bookings cadence.
• Pair trade: long a CRM vendor with clearer enterprise monetization and shorter sales-cycle exposure versus short HUBS over the next 2-3 quarters; the relative trade is cleaner than a single-name short.
• Revisit HUBS long only after two consecutive quarters of improving billings linearity or evidence that AI trials are shortening conversion time; that is the first credible signal the de-rating is over.